Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) has reported a loss for its first fiscal quarter (ending March 31) of $-2.03 versus a loss $-2.33 for the same period a year ago. E.P.S. were $-8.03 for the latest four quarters through March 31 versus $-10.25 for the same period a year ago.
Recent Price Action
On 5/2/24, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) stock declined slightly by -0.2%, closing at $43.20. NORMAL trading volume accompanied the decline. The stock has declined -2.4% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
RARE’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to be a modest Value Builder.
Ultragenyx Pharmaceutical has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Ultragenyx Pharmaceutical has a very low Appreciation Score of 3 but a good Power Rating of 83, and the Negative Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment